Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

Priya Vart; Niels Jongs; David C Wheeler; Hiddo J L Heerspink; Anna Maria Langkilde; Glenn M Chertow

doi:10.1001/jamanetworkopen.2023.10877

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

JAMA Netw Open. 2023 Apr 3;6(4):e2310877. doi: 10.1001/jamanetworkopen.2023.10877.

Authors

Priya Vart¹, Niels Jongs¹, David C Wheeler², Hiddo J L Heerspink^{1

3}, Anna Maria Langkilde⁴, Glenn M Chertow^{5

6}

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
² Department of Renal Medicine, University College London, London, United Kingdom.
³ The George Institute for Global Health, Sydney, Australia.
⁴ BioPharmaceuticals R&D, AstraZeneca, Gotherburg, Sweden.
⁵ Department of Medicine, Stanford University School of Medicine, Stanford, California.
⁶ Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.

No abstract available

Plain language summary

This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black vs White patients with chronic kidney disease (CKD) in North and South America.

Publication types

Randomized Controlled Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Glucosides / therapeutic use
Humans
Hypoglycemic Agents
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
White*

Substances

dapagliflozin
Glucosides
Hypoglycemic Agents

Associated data

ClinicalTrials.gov/NCT03036150